Comparative Pharmacology
Head-to-head clinical analysis: DEXAIR versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAIR versus FLUDROCORTISONE ACETATE.
DEXAIR vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEXAIR (dexamethasone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., cytokines, prostaglandins). It also inhibits leukocyte infiltration and reduces capillary permeability.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Inhalation: 2 inhalations (80 mcg each) twice daily, maximum 640 mcg/day.
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Terminal elimination half-life: 3.0-4.5 hours in adults with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Renal (urinary): ~65-75% as unchanged drug and metabolites; biliary/fecal: ~20-30% as metabolites; less than 10% unchanged in bile.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid